Study of Neurologic Development of Temporal Voice Area (TVA) in Deaf Infant
NCT ID: NCT02379611
Last Updated: 2021-10-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
41 participants
INTERVENTIONAL
2015-09-02
2020-10-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
At 24 months of age, the neurologic development of TVA of deaf infant implanted before the age of 18 months would be similar to the development of a normally hearing infant.
Main aim The main aim of the research is to study, by means of functional near infrared spectroscopy (fNIRS), the neurologic development of the TVA at 24 months of age (+/- 1 month) in a group (n=40) of normally hearing infant and in a group (n=40) of profound congenital deaf children implanted before the age of 18 months.
Main outcome Measure and localization of an increase of brain blood flow during an auditory stimulation "voice" type compared to a stimulation "non-voice" type. Comparison of the results between groups at 24 months of age +/- 1 month allows to analyse eventual differences.
Secondary aims and outcomes To study by means of functional near infrared spectroscopy the neurologic development of the temporal voice area at 12 months of age (+/- 1 month) in a group of normally hearing infant and in a group of profound congenital deaf infant wearing a standard hearing device between the age of 11 and 13 months and who will receive a cochlear implant between 12 and 18 months of age.
To study the association between fNIRS data and clinical data of the evaluation of comprehension of the spoken language at 24 months of age.
Methods Two groups of 40 infants matching in age will be constituted. Less than 13 months old children will be included during a medical consultation in the ENT department of Necker hospital after complete information of both parents. Written consent of both parents will be required. An audiophonological checking will be done.
Then a fNIRS examination will be programmed at the maternity of the Robert Debré hospital and done at the age of 12 months (+/- 1 month) and 24 months (+/-1 month). A fNIRS examination will be programmed at 36 months of age (+/- 1 month) for patinets included in the first year of the study.
This fNIRS examination measures the modifications in brain blood flow during the listening of human voice sound and environmental sound.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Main aim and outcome:
Main aim of the research is to compare cortical activation in the TVA at 24 months of age (+/- 1 month), by means of the measure of hemoglobin and/or desoxyhemoglobin concentration in the TVA during listening of human voice sound compared to non-voice sound (environmental sounds) (fNIRS method):
* in normally hearing infants
* in profound congenital deaf infants who received a standard auditory device before the age of 10 months and who were implanted between 12 and 18 months of age.
Comparison of the results in these two groups at 24 months +/- 1 month will allow to evaluate the impact of hearing loss and of its rehabilitation by means of standard hearing device and then by cochlear implant on neurologic development of the TVA in infant.
Main outcome is the recording of a difference in the measure of hemoglobin and/or desoxyhemoglobin concentration during listening of human voice sounds compared to environmental sounds in the TVA, in both groups of infants at 24 months old (+/- 1 month). A difference in localization of activations in the "deaf" group would suggest a modification of the neuro-development of the TVA due to the hearing loss. On the contrary, a similar localization of activated areas would suggest a "picking up" of the neuro-development of TVA due to the correction of hearing loss by means of an auditory device.
Secondary aims and outcomes
Compare cortical activation in the TVA at 12 months of age (+/- 1 month) by means of the measure of hemoglobin and/or desoxyhemoglobin concentration in the TVA during listening of human voice sounds compared to environmental sounds:
* in normally hearing infants
* in profound congenital deaf infants who received a standard auditory device before the age of 10 months and who were implanted between 12 and 18 months of age.
Secondary outcome is the recording of a difference in the measure of hemoglobin and / or desoxyhemoglobin concentration in the TVA during listening of human voice sounds compared to environmental sounds in both groups of infants at 12 months of age (+/- 1 month).
Comparison of the results in these two groups at 12 months +/- 1 month will allow to evaluate the impact of hearing loss and of its rehabilitation by means of standard hearing device and then by cochlear implant on neurologic development of the TVA in infant.
Comparison of results obtained at 12 months (+/- 1 month) and 24 months (+/- 1 month) of age in both groups will allow the study of neurological development of TVA in normally hearing infants and in deaf infants wearing an auditory device for a period of one year.
Study association between development of oral communication, measured by means of questionnaire of evaluation of communication development and of comprehension of oral language in infant, and activation of TVA at 24 months of age by means of fNIRS.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
normally hearing children
fNIRS (Functional Near Infrared Spectroscopy)
fNIRS is a non-invasive imaging method involving the quantification of chromophore concentration resolved from the measurement of near infrared (NIR) light attenuation, temporal or phasic changes. NIR spectrum light takes advantage of the optical window in which skin, tissue, and bone are mostly transparent to NIR light in the spectrum of 700-900 nm, while hemoglobin (Hb) and deoxygenated-hemoglobin (deoxy-Hb) are stronger absorbers of light. Differences in the absorption spectra of deoxy-Hb and oxy-Hb allow the measurement of relative changes in hemoglobin concentration through the use of light attenuation at multiple wavelengths.
Congenital profound deaf children
fNIRS (Functional Near Infrared Spectroscopy)
fNIRS is a non-invasive imaging method involving the quantification of chromophore concentration resolved from the measurement of near infrared (NIR) light attenuation, temporal or phasic changes. NIR spectrum light takes advantage of the optical window in which skin, tissue, and bone are mostly transparent to NIR light in the spectrum of 700-900 nm, while hemoglobin (Hb) and deoxygenated-hemoglobin (deoxy-Hb) are stronger absorbers of light. Differences in the absorption spectra of deoxy-Hb and oxy-Hb allow the measurement of relative changes in hemoglobin concentration through the use of light attenuation at multiple wavelengths.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
fNIRS (Functional Near Infrared Spectroscopy)
fNIRS is a non-invasive imaging method involving the quantification of chromophore concentration resolved from the measurement of near infrared (NIR) light attenuation, temporal or phasic changes. NIR spectrum light takes advantage of the optical window in which skin, tissue, and bone are mostly transparent to NIR light in the spectrum of 700-900 nm, while hemoglobin (Hb) and deoxygenated-hemoglobin (deoxy-Hb) are stronger absorbers of light. Differences in the absorption spectra of deoxy-Hb and oxy-Hb allow the measurement of relative changes in hemoglobin concentration through the use of light attenuation at multiple wavelengths.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Isolated congenital bilateral profound deafness
* Bilateral conventional hearing equipment between 2 and 10 months of life
* Rehabilitation project by cochlear implantation between 12 and 18 months accepted by parents
* French speaking parents
* Normal eardrums on otoscopy
* Signature of consent by both parents or by the sole parent with parental authority
* Beneficiary of a french social security (excluding AME)
* Any infant, followed in ORL consultation for any reason other than deafness, aged between 11 and 13 months at the time of the first fNIRS imaging examination.
* normal otoscopic examination
* Parents speaks French
* Signature of consent by both parents or by the sole parent with parental authority
* Stay in intensive care unit
* Premature birth
* Proven neuro-pediatric disorder
* Acquired deafness
* Stay in intensive care unit
* Premature birth
* Proven neuro-pediatric disorder
Exclusion Criteria
13 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre National de la Recherche Scientifique, France
OTHER
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
University of Paris 5 - Rene Descartes
OTHER
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Natalie Loundon, MD
Role: PRINCIPAL_INVESTIGATOR
Assistance Publique
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Necker Enfants malades Service d'ORL
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HAO13016
Identifier Type: OTHER
Identifier Source: secondary_id
P130706
Identifier Type: -
Identifier Source: org_study_id